{"id":962503,"date":"2026-05-13T21:44:37","date_gmt":"2026-05-14T01:44:37","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/park-dental-partners-announces-first-quarter-2026-results\/"},"modified":"2026-05-13T21:44:37","modified_gmt":"2026-05-14T01:44:37","slug":"park-dental-partners-announces-first-quarter-2026-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/park-dental-partners-announces-first-quarter-2026-results\/","title":{"rendered":"Park Dental Partners Announces First Quarter 2026 Results"},"content":{"rendered":"
\n

MINNEAPOLIS, May 13, 2026 (GLOBE NEWSWIRE) — Park Dental Partners, Inc. (NASDAQ: PARK) and affiliated dental practices (\u201cPark Dental Partners,\u201d \u201cwe,\u201d \u201cour,\u201d \u201cus,\u201d or the \u201cCompany\u201d) today reported its first-quarter financial results for 2026.\u00a0\u00a0 Summary financial results are listed below and in the accompanying supplemental financial tables.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n (Unaudited, in millions, except per share data, and Doctor counts)<\/em>
\n \n <\/td>\n<\/tr>\n
\u00a0<\/td>\n\n Three Months Ended<\/strong>
\n
\n March 31,<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\n 2026<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\n 2025<\/strong>\n <\/td>\n\u00a0<\/td>\n\n Change<\/strong>
\n \n <\/td>\n		\u00a0<\/td>\n<\/tr>\n
Revenue<\/td>\n$62.7<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$59.0<\/td>\n\u00a0<\/td>\n6.2%<\/td>\n\u00a0<\/td>\n<\/tr>\n
Gross Margin<\/td>\n$6.4<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$9.9<\/td>\n\u00a0<\/td>\n(35.3%)<\/td>\n\u00a0<\/td>\n<\/tr>\n
Gross Margin percentage<\/td>\n\u00a0<\/td>\n10.2%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n16.7%<\/td>\n\u00a0<\/td>\n(650 bps)<\/td>\n\u00a0<\/td>\n<\/tr>\n
Net Income (Loss)<\/td>\n($0.4)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$1.6<\/td>\n\u00a0<\/td>\n(124.9%)<\/td>\n\u00a0<\/td>\n<\/tr>\n
Diluted EPS<\/td>\n($0.09)<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$0.88<\/td>\n\u00a0<\/td>\n($0.97)<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted Gross Margin(a)<\/sup><\/td>\n$12.2<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$11.9<\/td>\n\u00a0<\/td>\n2.6%<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted Gross Margin Percentage(a)<\/sup><\/td>\n\u00a0<\/td>\n19.5%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n20.2%<\/td>\n\u00a0<\/td>\n(70 bps)<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted EBITDA(<\/sup>b<\/sup>)<\/sup><\/td>\n$4.7<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$5.5<\/td>\n\u00a0<\/td>\n(13.2%)<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted EBITDA margin(<\/sup>b<\/sup>)<\/sup><\/td>\n\u00a0<\/td>\n7.6%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n9.3%<\/td>\n\u00a0<\/td>\n(170 bps)<\/td>\n\u00a0<\/td>\n<\/tr>\n
Adjusted Diluted EPS(<\/sup>c<\/sup>)<\/sup><\/td>\n$0.44<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n$1.14<\/td>\n\u00a0<\/td>\n($0.70)<\/td>\n\u00a0<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
Same Practice Revenue Growth<\/td>\n\u00a0<\/td>\n4.1%<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n1.2%<\/td>\n\u00a0<\/td>\n290 bps<\/td>\n\u00a0<\/td>\n<\/tr>\n
Practicing Affiliated Doctors<\/td>\n\u00a0<\/td>\n221<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n\u00a0<\/td>\n203<\/td>\n\u00a0<\/td>\n8.9%<\/td>\n\u00a0<\/td>\n<\/tr>\n<\/table>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0
(a)\u00a0\u00a0\u00a0See Non GAAP Reconciliation of Gross Margin to Adjusted Gross Margin below
(b)\u00a0\u00a0\u00a0See Non GAAP Reconciliation of Net Income (Loss) to Adjusted EBITDA below
(c)\u00a0\u00a0\u00a0See Non GAAP Reconciliation of Earnings (Loss) Per Share to Adjusted Earnings Per Share below<\/p>\n

\n
\n
Executive Commentary \u2013 Pete Swenson, Chief Executive Officer and Chair of the Board of Directors<\/strong>\n <\/p>\n

\u201cWe delivered a solid start to 2026, with revenue increasing 6.2% year over year, driven by strong same practice performance and continued patient demand. Results were consistent with our expectations and reflect continued execution against our operating plan. We continue to invest in recruiting, staffing, and clinical capacity to support long-term growth.<\/p>\n

With strong liquidity and a flexible balance sheet, we remain well positioned to execute on our growth strategy, including expanding current practices and adding new practices through disciplined acquisitions and de novo expansion.\u201d<\/p>\n

\n Financial Results \u2013 First Quarter 2026<\/strong>\n <\/p>\n